BTIG Reiterates Rating on RNAC $RNAC
Key Points
- BTIG now rates Cartesian Therapeutics, Inc. ($RNAC) "buy" with a $44.00 target.
- The Street's average $RNAC price target is $34.57 (Strong Buy).
- $RNAC last traded around $8.40.
BTIG reiterated its rating on Cartesian Therapeutics, Inc. ($RNAC) to a "buy" rating, with a price target of $44.00 in a recent research note.
Cartesian Therapeutics, Inc. ($RNAC) Stock
Cartesian Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.